Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid (NCT07311772) | Clinical Trial Compass
RecruitingPhase 3
Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid
China386 participantsStarted 2025-12-16
Plain-language summary
To explore the efficacy of Houyanqing Oral Liquid combined with conventional treatment in preventing and treating radiation-induced oral mucositis, so as to improve the quality of life of nasopharyngeal carcinoma patients received radiotherapy.
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Staged as Stage I-IV according to the 9th edition of the TNM Classification of Malignant Tumors formulated by the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC);
✓. Age: 18 to 75 years old;
✓. Karnofsky Performance Status (KPS) score ≥ 80 before treatment;
✓. No oral diseases (such as oral mucositis or salivary gland damage) before radiotherapy;
✓. Requiring radical radiotherapy;
✓. The patient has signed the informed consent form and is willing and able to comply with the study's follow-up visits, treatment plan, laboratory tests, and other research procedures.
Exclusion criteria
✕. Patients with confirmed tumor recurrence, distant tumor metastasis, or who have received other anti-tumor treatments;
✕. Previous history of head and neck radiotherapy;
✕. Known allergy to the drugs used in this study (Houyanqing Oral Liquid, any conventional treatment drugs);
✕. Local use of Houyanqing Oral Liquid, Recombinant Human Epidermal Growth Factor (rhEGF) Topical Solution, Vitamin B12 Solution, or Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) mouthwash in the oral cavity within one month before enrollment;
✕. Comorbidities requiring long-term treatment with immunosuppressive drugs, or systemic/local use of corticosteroids at immunosuppressive doses before enrollment;
What they're measuring
1
Incidence of ≥ Grade II radiation-induced oral mucositis
Timeframe: From the start of radical radiotherapy to the 3 months after the completion of radiotherapy